Merck & Co (MRK) Aktie Kurs

Merck & Co Kurs

NYSE·LUKKET
145,27
​
Markedet lukket

Merck & Co aktiekurs

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Merck & Co aktie og aktieanalyse

The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards.

Hyppigt stillede spørgsmål om Merck & Co-aktien

The business model of Merck & Co Inc is centered around the development, manufacturing, and marketing of innovative pharmaceutical products and vaccines. Merck's primary aim is to improve and save lives by addressing unmet medical needs. Through rigorous research and development, the company focuses on discovering novel therapies and delivering them to patients worldwide. Merck operates across various therapeutic areas, including oncology, infectious diseases, vaccines, cardiovascular health, and more. By combining scientific expertise with a strong commitment to patients and healthcare professionals, Merck continually strives to advance medical science and make a positive impact on global health.

Merck & Co Inc is primarily active in the pharmaceutical and healthcare industries.

The main competitors of Merck & Co Inc in the market are Johnson & Johnson, Pfizer Inc, Novartis AG, and Bristol-Myers Squibb Company.

Merck & Co Inc is a renowned pharmaceutical company with a rich history and notable background. Established in 1891, Merck & Co Inc has been dedicated to enhancing global health and improving people's lives. The company has evolved into one of the leading players in the pharmaceutical industry, specializing in research, development, and manufacturing of innovative medications and vaccines. Merck & Co Inc has proactively contributed to medical advancements, from pioneering treatments for diseases like HIV/AIDS to addressing various health challenges. With a commitment to scientific excellence and patient well-being, Merck & Co Inc continues to shape the future of healthcare worldwide.

Merck & Co Inc, a leading pharmaceutical company, has achieved significant milestones throughout its history. The company's notable achievements include the development and launch of groundbreaking drugs like Gardasil, a vaccine for preventing cervical cancer, and Keytruda, an innovative immunotherapy for treating various types of cancer. Merck & Co Inc has also contributed to medical advancements with its research and development efforts, resulting in breakthroughs in areas such as HIV/AIDS treatment and vaccines. The company's commitment to improving global health has resulted in partnerships and initiatives aimed at tackling diseases like malaria and Ebola. Merck & Co Inc continues to make strides in the pharmaceutical industry, focusing on innovative solutions for unmet medical needs.

Merck & Co Inc is primarily present in several countries and regions across the world. The company has a strong global presence, with operations in the United States, Europe, Asia-Pacific, Latin America, and Africa. Merck & Co Inc has established a significant presence in key markets such as the United States, Germany, Japan, China, and Brazil. With its wide international footprint, Merck & Co Inc is committed to delivering its innovative healthcare solutions to patients and healthcare professionals worldwide.

Merck & Co Inc represents a strong commitment to scientific innovation, integrity, and improving global health. As a leading pharmaceutical company, Merck aims to discover, develop, and provide high-quality healthcare solutions. The company's corporate philosophy revolves around putting patients first, valuing diversity and inclusion, and taking responsibility for environmental sustainability. Merck is dedicated to delivering innovative medicines and vaccines, ensuring affordability and access for patients worldwide. With a focus on research, collaboration, and ethical business practices, Merck strives to make a positive impact on society and enhance the well-being of individuals around the globe.

Omregnet til den aktuelle valutakurs handles Merck & Co-aktien til 129,69 EUR (145,27 USD).

Merck & Co-aktien (MRK) er noteret på 11 børser, herunder: NYSE (MRK), London (0QAH.L), SIX (Zürich) (MRK1.SW), XETRA (6MK.DE), Frankfurt (6MK.F), München (6MK.MU), Düsseldorf (6MK.DU), Hamburg (6MK.HM).

Merck & Co Inc is one of the leading global pharmaceutical companies focused on the discovery, development, and marketing of drugs, vaccines, and biologics for a variety of diseases and disorders. The company is headquartered in Kenilworth, New Jersey and operates worldwide in over 140 countries.

Omsætningen kan for øjeblikket ikke beregnes for Merck & Co.

Overskuddet kan for øjeblikket ikke beregnes for Merck & Co.

P/E-forholdet kan ikke beregnes for Merck & Co i øjeblikket.

P/S-forholdet kan ikke beregnes for Merck & Co i øjeblikket.

AlleAktien-kvalitetsscore kan ikke beregnes for Merck & Co i øjeblikket.

ISIN for Merck & Co er US58933Y1055. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Merck & Co er A0YD8Q. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Merck & Co er MRK. Tickersymbolet bruges til at handle Merck & Co-aktier på børsen.

Fair værdiTerminal
136,55 USD
Over-/underværdieringTerminal
Fair værdieret
Sektor
Industri
Farmaceutikalier
Antal aktier
Medarbeidere
Omsætningsvækst Ø5 år
EBIT-vækst Ø5 år
Resultatvækst Ø5 år
Hjemmeside merck.com
Land
Valuta
USD
Børsintroduktion
—
ISIN
US58933Y1055
CUSIP
58933Y105
SEDOL
2778844
Markedsværdi
52-ugers interval
AAQS
2 / 10
PEG-forhold
—
P/E-forhold
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
K/B-forhold
0,00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
17,85 %
Sidst opdateret 24. okt. 2026, 09.13

Merck & Co Ticker

DÜSSELDORF · 6MK.DUFRANKFURT · 6MK.FHAMBURG · 6MK.HMLONDON · 0QAH.LMAILAND · 1MRKX.MIMÜNCHEN · 6MK.MUNEW YORK · MRKPARIS · MRK.PASIX · MRK1.SWWIEN · MRK.VIXETRA · 6MK.DE

Merck & Co FIGI

MRK:US · BBG000BPD168MRK:UA · BBG000BPD1D0MRK:UC · BBG000BPD1P7MRK:UN · BBG000BPD257MRK:UP · BBG000BPD2C9MRK:UB · BBG000BPD2Y5MRK:UT · BBG000BPD3Q2MRK:UM · BBG000BPD408MRK:UX · BBG000BPD4Y1MRK:UD · BBG000BPD7Q3MRK:UF · BBG000BPDB66MRK:VY · BBG000BPDBK0

Alle fundamentale data om Merck & Co i deep dive

Vores aktieanalyse af Merck & Co-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Merck & Co. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: